LRRC34 Inhibitors
LRRC34 inhibitors encompass a spectrum of chemical entities designed to inhibit the functional activity of LRRC34 through diverse biochemical pathways. Cyclosporin A binds to cyclophilins and inhibits calcineurin, thereby indirectly reducing the activity of LRRC34, which may play a role in immune response regulation. Rapamycin, targeting the mTOR pathway, curtails cellular growth signals that could influence LRRC34 activity, while Bortezomib thwarts proteasomal protein degradation, potentially affecting LRRC34 stability if it is involved in protein turnover. Trichostatin A, on the other hand, modulates gene expression by inhibiting histone deacetylases, which may lead to alterations in LRRC34 expression if it is associated with chromatin remodeling. PD 98059 and U0126, both MEK inhibitors, disrupt the MAPK/ERK signaling axis, which could result in downregulation of LRRC34 if it is implicated in cell growth and differentiation.
Further expanding the arsenal, LY 294002, a PI3K inhibitor, could diminish LRRC34 activity by attenuating the PI3K/Akt signaling pathway, often linked with cellular survival and growth factor responses. Inhibitors such as WZB117 and 2-Deoxy-D-glucose, which target glucose uptake and glycolysis, respectively, could indirectly suppress LRRC34 activity by modulating metabolic pathways. Thapsigargin disrupts calcium homeostasis by inhibiting SERCA pumps, potentially diminishing LRRC34 function if calcium signaling is crucial for its activity. Geldanamycin, an Hsp90 inhibitor, could destabilize LRRC34 if it requires Hsp90 for correct protein folding. Lastly, SB 203580, a p38 MAPK inhibitor, might reduce LRRC34 activity by altering signaling in inflammatory and stress response pathways, assuming LRRC34 is a participant in these processes. Collectively, these compounds, through their targeted actions on various signaling and metabolic pathways, are poised to inhibit LRRC34 function without affecting protein expression levels directly.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A binds to the cyclophilins and inhibits calcineurin. By suppressing the calcium-dependent dephosphorylation process, it indirectly diminishes the activity of LRRC34, which is posited to be involved in immune responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that impedes cellular signaling pathways related to proliferation and survival. By inhibiting mTOR signaling, it can reduce the activity of proteins such as LRRC34 that are involved in cell cycle regulation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor, preventing the degradation of proteins involved in cell cycle control. Through proteasome inhibition, it could lead to altered signaling that indirectly diminishes LRRC34 function if LRRC34 is involved in the regulation of protein turnover. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By altering the acetylation status of histones, it can change the expression patterns of genes including those like LRRC34 that may be involved in chromatin remodeling and gene expression control. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that impedes the MAPK/ERK pathway. Since LRRC34 could be implicated in cell growth and differentiation, inhibition of this pathway may lead to downregulation of LRRC34's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that blocks the PI3K/Akt pathway. By reducing signaling through this pathway, it can indirectly reduce the functional activity of proteins like LRRC34 that may be associated with growth factor signaling. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
WZB117 is a glucose transporter 1 (GLUT1) inhibitor, which may lead to diminished glycolytic activity in cells. If LRRC34 is involved in metabolic regulation, inhibiting glycolysis could indirectly reduce LRRC34 activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
2-Deoxy-D-glucose acts as a glycolysis inhibitor by mimicking glucose. If LRRC34 is implicated in cellular energy homeostasis, inhibition of glycolysis may lead to a reduction in LRRC34 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that disrupts calcium homeostasis. If LRRC34's function is dependent on calcium signaling, interfering with calcium levels could diminish its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that hinders the MAPK/ERK pathway. As LRRC34 may have a role in signaling pathways that regulate cell proliferation, inhibition of MEK can indirectly decrease LRRC34 function. | ||||||